目的 本研究旨在探讨人类表皮生长因子受体2 (humman epidermal growth factor receptor 2, HER2)阳性(+)乳腺癌患者蒽环类药物相关急性心脏毒性 (anthracycline-induced cardiotoxicity, ACT) 的危险因素,并构建其诺曼图(nomogram)预测模型,以期为此类患者的预测、诊断与预防提供理论依据。方法 回顾性分析我院2016年1月至2021年12月收治的HER2+乳腺癌患者319例,根据蒽环类药物化疗后是否发生急性ACT将其分成急性ACT组(n=149)与无急性ACT组(n=170)。采用多因素Logistic回归分析探讨HER2+乳腺癌患者发生急性ACT的影响因素,并进一步用R软件建立nomogram预测模型。结果 两组患者在年龄、身体质量指数(body mass index, BMI)、高血压病史、高血脂病史、糖尿病病史、联合曲妥珠单抗、联用右丙亚胺、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-H)、肌酸激酶同工酶(CK-MB)及α-羟丁氨酸脱氢酶(α-HBDH)方面比较,差异有统计学意义(P＜0.05)。多因素Logistic回归分析显示,BMI、糖尿病病史、联合曲妥珠单抗、联合右丙亚胺、LDL-H、CK-MB是HER2+乳腺癌患者发生急性ACT的危险因素(P＜0.05)。以上述危险因素为指标构建nomogram预测模型,一致性指数(C-Index)为0.870,Hosmer-Lemeshow拟合优度检验结果显示,该预测模型的拟合效果良好(χ2 =11.180,P=0.192)。结论 BMI、糖尿病病史、联合曲妥珠单抗、联合右丙亚胺、LDL-H、CK-MB是HER2+乳腺癌患者发生急性ACT的危险因素,基于上述危险因素构建的nomogram预测模型具有良好的区分度及准确性,可有效识别高危患者,对临床有一定的指导意义。
Abstract
OBJECTIVE To explore the risk factors of acute cardiotoxicity (ACT) in humman epidermal growth factor receptor 2+(HER2+) breast cancer patients caused by anthracyclines, and construct its nomogram prediction model, in order to provide theoretical basis for the prediction, diagnosis and prevention of such patients. METHODS A total of 319 patients with HER2+ breast cancer treated in our hospital from January 2016 to December 2021 were included and divided into ACT group (n=149) and no ACT group (n=170) according to whether ACT occurred after anthracycline chemotherapy. The clinical data of all patients were collected, and the influencing factors of ACT in HER2+ breast cancer patients were investigated by multivariate logistic regression analysis. The risk factors were introduced into R 4.2.0 software. RESULTS Significant differences between the two groups were shown in the age, BMI, history of hypertension, history of hyperlipidemia, history of diabetes, combination of trastuzumab, combination of cardioprotective drugs dextropropimine, total cholesterol(TC)、low density lipoprotein-cholesterol(LDL-H), creatine kinase-myocardial band isoenzyme(CK-MB), α-hydroxybutyrate dehydrogenase (α-HBDH)(P<0.05). The results of multivariate logistic regression analysis showed that BMI, history of diabetes, trastuzumab combined with dextropropamine, LDL-H and CK-MB were the risk factors of ACT in HER2+ breast cancer patients (P<0.05). Nomogram prediction model was constructed with the above risk factors as indicators. The area under ROC curve was 0.870(95%CI:0.831, 0.909), and the calibration curve of the prediction model was basically consistent with the actual curve. Hosmer lemeshow goodness of fit test showed that the prediction model had a good fitting effect(χ2=11.180,P=0.192). CONCLUSION BMI, history of diabetes, combined trastuzumab, combination with dextropropimine, LDL-H and CK-MB are the risk factors of ACT in patients with HER2+ breast cancer. The nomogram prediction model has good differentiation ability and accuracy and can effectively identify the high-risk patients.
关键词
人类表皮生长因子受体2阳性乳腺癌 /
蒽环 /
化疗 /
急性心脏毒性 /
危险因素 /
诺曼图
{{custom_keyword}} /
Key words
HER2+ breast cancer /
anthracycline /
chemotherapy /
acute cardiotoxicity /
risk factor /
nomogram
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209-249.
[2] LOIBL S, GIANNI L. HER2-positive breast cancer. The Lancet, 2016, 389(10087):169-179.
[3] RASOTTO R, CALIARI D, CASTAGNARO M, et al. An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol, 2011, 144(2-3):170-179.
[4] INTERNATIONAL MEDICAL AND EXCHANGE BRANCH OF CHINA ANTI CANCER ASSOCIATION,BREAST CANCER GROUP,CANCER DOCTOR BRANCH,CHINESE MEDICAL DOCTOR ASSOCIATION. Consensus on clinical diagnosis and treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (2022 version). Chin J Oncol(中华肿瘤杂志),2022,44(12):1288-1295.
[5] HONG Y J, PARK H S, PARK J K, et al. Early detection and serial monitoring of Anthracycline-Induced cardiotoxicity using T1-mapping cardiac magnetic resonance imaging:an animal study. Sci Rep, 2017,7(1):2663. Doi: 10.1038/s41598-017-02627-x.
[6] BREAST CANCER PROFESSIONAL COMMITTEE OF CHINA ANTI CANCER ASSOCIATION. Guidelines and specifications for breast cancer diagnosis and treatment of China anti cancer association (2021 version). Chin Oncol(中国癌症杂志), 2021,31(10):954-1040.
[7] CHATTERJEE K, ZHANG J, HONBO N, et al. Doxorubicin Cardiomyopathy. Cardiology, 2010, 115(2):155-162.
[8] HEFTI E, BLANCO J G. Anthracycline-related cardiotoxicity in patients with acute myeloid leukemia and down syndrome:a literature review. Cardiovasc Toxicol, 2016, 16(1):5-13.
[9] GHIGNATTI PVDC, NOGUEIRA L J, LEHNEN A M, et al. Cardioprotective effects of exercise training on doxorubicin-induced cardiomyopathy:a systematic review with meta-analysis of preclinical studies. Sci Rep, 2021,11(1):6330. Doi:10.1038/s41598-021-83877-8.
[10] LIEN C Y, JENSEN B T, HYDOCK D S, et al. Short-term exercise training attenuates acute doxorubicin cardiotoxicity. J Physiol Biochem, 2015,71(4):669-678.
[11] CHOTENIMITKHUN R, D′AGOSTINO R J R, LAWRENCE J A, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol, 2015,31(3):302-307.
[12] BEHESHTI A T, TOROGHI H M, HOSSEINI G, et al. Carvedilol administration can prevent doxorubicin-Induced cardiotoxicity:a double-blind randomized trial. Cardiology, 2016,134(1):47-53.
[13] ZVINOBSKI F, STEPHENS J A, RAMASWAMY B, et al. A cardiac rehabilitation program for breast cancer survivors:a feasibility study. J Oncol, 2021:9965583. Doi:10.1155/2021/9965583.
[14] IACOPO F, RANCH M, CARDINALE D, et al. Preventive cardio-oncology:cardiovascular disease prevention in cancer patients and survivors. Curr Treat Options Cardiovasc Med, 2021, 23(1). Doi:10.1007/s11936-020-00883-1
[15] ZHAO Y, LI H Y, YUAN L, et al. Advances in structural modification and antitumor activity of anthracyclic compounds. Chin Pharm J(中国药学杂志), 2016,51(12):953-961.
[16] HE F, BO M M, LIANG X, et al. Retrospective study on the occurrence and influencing factors of anthracycline induced acute cardiac toxicity in patients with breast cancer. Chin Pharm J(中国药学杂志), 2017,52(12):1089-1092.
[17] CHERAGHI Z, AYUBI E, DOOSTI-IRANI A. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer:methodologic issues to avoid misinterpretation in the meta-analysis. J Clin Oncol, 2017,35(8):923. Doi: 10.1200/JCO.2016.71.0715.
[18] DONG X J, SHANG R R, LIU X H. Incidence and risk factors of prolonged corrected QT interval in patients with breast cancer induced by anthracycline drugs. Chin J Gen Pract(中华全科医师杂志), 2020,19(6):507-511.
[19] ARMENIAN S H, SUN C L, SHANNON T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood, 2011,118(23):6023-6029.
[20] ARMSTRONG G T, OEFFINGER K C, CHEN Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol, 2013,31(29):3673-3680.
[21] SUN F Y, WANG H F, SHI J, et al. Effect of epirubicin based chemotherapy on cardiac toxicity in patients with breast cancer and diabetes. Chin Gen Pract(中国全科医学), 2017,20(15):1898-1902.
[22] BELMONTE F, DAS S, SYAS-SHAH P, et al. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol, 2015, 309(8):H1271-H1280.
[23] HOU H, LIN C, ZHANG M, et al. Research progress on cardiotoxicity and molecular mechanism induced by new anti-tumor drugs. Chin Pharm J(中国药学杂志), 2022, 57(1):8-14.
[24] PENTASSUGLIA L, GRAF M, ANE H, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res, 2009, 315(7):1302-1312.
[25] LI T, PEI F Y, ZHANG T, et al. Rapid health technology assessment of dexamethasone for injection to reduce the incidence and severity of cardiotoxicity in patients with anthracycline induced tumors. Chin Pharm J(中国药学杂志), 2021, 56(21):1764-1769.
[26] CALVILLO-ARGUELLES O, ABDEL-QADIR H, MICHALOWSKA M, et al. Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol, 2019, 35(2):153-159.
[27] FENG Z L, SUN R T, QI J W, et al. Correlation between miRNA-142-5P and cTnI, CK-MB, MYO, markers of myocardial injury in patients with ACS. Chin J Clin Ratio Drug Use(临床合理用药杂志), 2014, 7(22):108-109.
[28] BEIJING HYOERTENSION ASSOCIATION, BEIJING DIABETES PREVENTION AND TREATMENT ASSOCIATION, BEIJING RESEARCH FOR CHRONIC DISEASES CONTROL AND HEALTH EDUCATION. Practice guide for comprehensive management of cardiovascular diseases at grassroots level 2020. Chin J Fro Med Sci(Electronic Version)(中国医学前沿杂志,电子版), 2020, 12(8):1-73.
[29] SUN X F, TANG Y, FAN Y Z, et al. Risk factors of acute diffuse brain swelling after head injury and construction of Nomogram prediction model. Pract J Cardiac Cereb Pneum Vasc Dis(实用心脑肺血管病杂志), 2022, 30(4):47-51.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
北京协和医学院护理学院院级科研课题资助(PUMCSON202102)
{{custom_fund}}
PDF(1644 KB)
